Preoperative Imaging of Hilar Cholangiocarcinoma
Executive Summary
Hilar cholangiocarcinoma (HCCA), also known as a Klatskin tumor, represents 60–70% of all cholangiocarcinoma cases. It is a complex malignancy arising at the biliary confluence, where surgical resection remains the only potentially curative treatment. However, nearly two-thirds of patients present with disease that is already beyond surgical correction due to frequent locoregional invasion.
The diagnostic paradigm has shifted significantly toward non-invasive cross-sectional imaging, specifically Multi-Row Detector Computed Tomography (MDCT) and Magnetic Resonance Imaging (MRI) with Magnetic Resonance Cholangiopancreatography (MRCP). These modalities have largely supplanted invasive procedures like Endoscopic Retrograde Cholangiography (ERC), which carry risks of perioperative infectious complications. Precise preoperative staging is critical to identify resectable cases and avoid non-therapeutic laparotomies, though identifying the true extent of the disease remains a challenge due to frequent underestimation of submucosal spread.
Disease Overview and Classification
Hilar cholangiocarcinoma is defined as an adenocarcinoma of the extra-hepatic biliary tree arising from the biliary confluence or the main left or right hepatic ducts.
Anatomical Classification
Cholangiocarcinomas (CC) are classified by their anatomical location:
Intrahepatic: 5–10% of cases.
Perihilar (HCCA): 60–70% of cases.
Distal: 20–30% of cases.
Bismuth-Corlette Classification
The Bismuth-Corlette system is utilized to categorize the pattern of involvement within the hepatic ducts:
Type I: Limited to the common hepatic duct, distal to the confluence.
Type II: Involves the primary biliary confluence.
Type IIIa: Involves the confluence and extends into the right secondary intrahepatic ducts.
Type IIIb: Involves the confluence and extends into the left secondary intrahepatic ducts.
Type IV: Involves the confluence and extends into bilateral secondary intrahepatic ducts, or represents multi-centric disease.
Morphological Growth Patterns
HCCA manifests in three primary growth patterns, which dictate their appearance on imaging:
Diagnostic and Imaging Modalities
Ultrasonography (US)
Transabdominal US is typically the first-line modality for evaluating jaundiced patients.
Strengths: High sensitivity (up to 100%) for detecting intrahepatic bile duct dilatation; useful for excluding gallstones. Doppler US can identify vascular encasement.
Limitations: Poor sensitivity for detecting metastases in lymph nodes (37%), liver (66%), and peritoneum (33%). It is often hindered by bowel gas and difficult anatomy.
Direct Cholangiography (ERCP and PTC)
While traditionally the gold standard for mapping segmental involvement, these invasive techniques are now used more selectively.
Diagnostic Utility: Sensitivity of 75–85% and accuracy of 95% for identifying the extent of the tumor. It allows for brush cytology and biopsy.
Limitations: Invasiveness increases infection risks. Biopsy sensitivity is low (10–80%) due to the desmoplastic reaction and low cellularity of many tumors. It cannot detect extraductal extension.
MDCT (Multi-Row Detector Computed Tomography)
MDCT provides high-quality multiplanar reconstructions essential for surgical planning.
Capabilities: Detects the primary tumor in 70–90% of cases. It is particularly effective at demonstrating involvement of the hepatic artery and portal vein.
Accuracy: Overall accuracy for assessing resectability ranges between 60% and 86%.
MRI and MRCP
MRI/MRCP is currently the imaging modality of choice for HCCA.
Performance: Nearly 100% sensitivity for diagnosing biliary obstruction and 88–95% accuracy in determining the cause of obstruction.
Advantages: Non-invasive; provides a comprehensive "map" of the biliary tree, vessels, and liver parenchyma. 3D-triggered sequences allow for high-resolution imaging of specific liver segments, including the caudate lobe.
Strategic Note: MRCP should be performed before biliary stenting, as stents cause inflammation that can mimic tumor spread.
FDG-PET Scanning
The role of PET is still evolving and is not yet routine.
Metastatic Detection: PET is 78% avid for CC and can identify occult metastatic disease in roughly 24% of patients, potentially altering management.
Limitation: Less helpful for infiltrating tumors and lacks sufficient data for routine preoperative use.
Surgical Considerations and Resectability
Determinants of Resectability
Surgical resection is curative but demanding, often requiring bile duct excision, portal lymphadenectomy, cholecystectomy, and partial hepatectomy. Resectability is dictated by:
Biliary Extent: Involvement of secondary biliary confluences.
Vascular Invasion: Involvement of the main portal vein trunk or bilateral involvement of hepatic arteries.
Liver Condition: Presence of lobar atrophy or extensive parenchymal invasion.
Metastasis: Presence of regional lymph node involvement or distant metastases.
Criteria Suggesting Unresectability
Severe bilateral involvement of secondary biliary confluences.
Involvement of the main trunk of the portal vein.
Bilateral involvement of the hepatic artery and portal vein.
Vascular involvement on one side with extensive bile duct involvement on the contralateral side.
Challenges in Staging
Understaging is common due to the limitations of imaging in detecting submucosal spread. Even with modern MDCT, resectability is correctly predicted in only approximately 60% of cases. In many instances, true resectability can only be determined through operative evaluation.
